12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bydureon exenatide regulatory update

EMA said that it is evaluating the potential pancreatic toxicity of glucagon-like peptide-1 (GLP-1) receptor ( GLP-1R; GLP1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. Last month, FDA said it was evaluating the potential pancreatic toxicity of antidiabetics (see BioCentury, March 18). EMA noted that the European labels for all GLP-1- and DPP-4-based treatments include warnings of pancreatitis. The agency said the risk management plans for the products also instruct marketing authorization holders to "closely monitor for adverse effects...

Read the full 402 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >